Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1-γ, and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese community hospital
Tóm tắt
Among the myositis-specific antibodies (MSA), anti-transcriptional intermediary factor 1 (TIF1)-γ and anti-nuclear matrix protein 2 (NXP2) antibodies are reportedly associated with cancer-associated myositis (CAM). We aimed to investigate patient characteristics of CAM and the clinical role of cancer-associated MSA (caMSA) in a retrospective cohort from a city hospital. All patients visiting our department between April 2014 and October 2021 with newly diagnosed dermatomyositis, polymyositis, and clinically amyopathic dermatomyositis were included. Anti-TIF1-γ and anti-NXP2 antibodies were collectively considered as caMSA. First, we compared clinical characteristics in CAM, defined as cases showing onset or recurrence of malignancy within 5 years, versus non-CAM. Second, we investigated independent risk factors for CAM. Third, we compared clinical characteristics with and without caMSA within CAM. Finally, we investigated whether caMSA was predictive of poor prognosis. The cohort of 39 patients included 12 (30.7%) CAM cases. Compared with non-CAM, CAM had significantly more dermatomyositis and higher frequencies of dysphagia, anti-TIF1-γ antibody, and caMSA. Using logistic regression analysis, caMSA was an independent risk factor for CAM. In a comparison between caMSA and non-caMSA within CAM, caMSA was associated with higher frequencies of stage ≥ II. However, caMSA did not necessarily indicate a poor prognosis. Only caMSA represented an independent risk factor for CAM and showed a significant association with advanced cancer.
Tài liệu tham khảo
Mimori T, Imura Y, Nakashima R, Yoshifuji H (2007) Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol 19:523–529. https://doi.org/10.1097/BOR.0b013e3282f01a8c
Dobloug GC, Svensson J, Lundberg IE, Holmqvist M (2018) Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study. Ann Rheum Dis 77:40–47. https://doi.org/10.1136/annrheumdis-2017-211402
Buchbinder R, Forbes A, Hall S, Dennett X, Giles G (2001) Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 134:1087–1095. https://doi.org/10.7326/0003-4819-134-12-200106190-00008
Yang H, Peng Q, Yin L et al (2017) Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies: a large longitudinal cohort study. Arthritis Res Ther 19:259. https://doi.org/10.1186/s13075-017-1469-8
Oldroyd A, Sergeant JC, New P et al (2019) The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis. Rheumatology (Oxford) 58:650–655. https://doi.org/10.1093/rheumatology/key357
Fujimoto M, Hamaguchi Y, Kaji K et al (2012) Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 64:513–522. https://doi.org/10.1002/art.33403
Li Y, Jia X, Sun X et al (2021) Risk factors for cancer-associated myositis: a large-scale multicenter cohort study. Int J Rheum Dis 24:268–273. https://doi.org/10.1111/1756-185X.14046
Ogawa-Momohara M, Muro Y, Mitsuma T, et al (2018). Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients. Clin Exp Rheumatol 36:990–995. https://www.clinexprheumatol.org/abstract.asp?a=12403. Accessed 10 Apr 2022
Ichimura Y, Matsushita T, Hamaguchi Y et al (2012) Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 71:710–713. https://doi.org/10.1136/annrheumdis-2011-200697
Ichimura Y, Konishi R, Shobo M et al (Online ahead of print). Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash. Rheumatology (Oxford). https://doi.org/10.1093/rheumatology/keab518
Bohan A, Peter JB (1975) Polymyositis and dermatomyositis. I N Engl J Med 292:344–347. https://doi.org/10.1056/NEJM197502132920706
Bohan A, Peter JB (1975) Polymyositis and dermatomyositis. II N Engl J Med 292:403–407. https://doi.org/10.1056/NEJM197502202920807
Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD (2006) A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 54:597–613. https://doi.org/10.1016/j.jaad.2005.10.041
Nakashima R, Imura Y, Hosono Y et al (2014) The multicenter study of a new assay for simultaneous detection of multiple anti-aminoacyl-tRNA synthetases in myositis and interstitial pneumonia. PLoS ONE 9:e85062. https://doi.org/10.1371/journal.pone.0085062
Sato S, Murakami A, Kuwajima A et al (2016) Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies. PLoS One 11:e0154285. https://doi.org/10.1371/journal.pone.0154285.10.1371/journal.pone.0154285
Fujimoto M, Murakami A, Kurei S et al (2016) Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis. J Dermatol Sci 84:272–281. https://doi.org/10.1016/j.jdermsci.2016.09.013
Hamaguchi Y, Kuwana M, Takehara K (2020) Performance evaluation of a commercial line blot assay system for detection of myositis- and systemic sclerosis-related autoantibodies. Clin Rheumatol 39:3489–3497. https://doi.org/10.1007/s10067-020-04973-0
Zidane M, Dressler C, Nast A, Egeberg A (2020). Incidences of different cancer types in dermatomyositis, polymyositis and dermatopolymyositis: results of a registry analysis. Br J Dermatol 183:186–188. https://doi.org/10.1111/bjd.18948
Oldroyd AGS, Allard AB, Callen JP et al (2021) A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. Rheumatology (Oxford) 60:2615–2628. https://doi.org/10.1093/rheumatology/keab166
Mugii N, Hasegawa M, Matsushita T et al (2016) Oropharyngeal dysphagia in dermatomyositis: associations with clinical and laboratory features including autoantibodies. PLoS ONE 11:e0154746. https://doi.org/10.1371/journal.pone.0154746
Rogers A, Chung L, Li S, Casciola-Rosen L, Fiorentino DF (2017) Cutaneous and systemic findings associated with nuclear matrix protein 2 antibodies in adult dermatomyositis patients. Arthritis Care Res (Hoboken) 69:1909–1914. https://doi.org/10.1002/acr.23210
Albayda J, Pinal-Fernandez I, Huang W et al (2017) Antinuclear matrix protein 2 autoantibodies and edema, muscle disease, and malignancy risk in dermatomyositis patients. Arthritis Care Res (Hoboken) 69:1771–1776. https://doi.org/10.1002/acr.23188
Kadoya M, Hida A, Hashimoto Maeda M et al (2016) Cancer association as a risk factor for anti-HMGCR antibody-positive myopathy. Neurol Neuroimmunol Neuroinflamm 3:e290. https://doi.org/10.1212/NXI.0000000000000290